BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to Capan-1 cell line is 128
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GLRX3 | 15987 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics and qRT-PCR and Western Blotting | Up | 0.56 | 0.0032 | 34794402 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 29130098 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by Western Blotting and SFA | NA | 0.48 | 0.5695 | 32781084 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by SFA and qRT-PCR | NA | 0.48 | 0.5695 | 30466404 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs followed by SP assay | NA | 0.48 | 0.5695 | 22963768 |
| SOX9 | 11204 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | RT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.0244 | 28984791 |
| SOX9 | 11204 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by Western Blotting and SFA | NA | 0.48 | 0.0244 | 32781084 |
| SOX9 | 11204 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by SFA and qRT-PCR | NA | 0.48 | 0.0244 | 30466404 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | Gemcitabine | qRT-PCR followed by IHC staining | NA | 0.44 | 0.6448 | 23026911 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by Western Blotting and SFA | NA | 0.44 | 0.6448 | 32781084 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by qRT-PCR | NA | 0.44 | 0.6448 | 30819221 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | Gemcitabine | qRT-PCR followed by IHC staining | NA | 0.44 | 0.7582 | 23026911 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | Gemcitabine | FACs followed by SFA and IF staining | NA | 0.44 | 0.7582 | 22320450 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by qRT-PCR | NA | 0.44 | 0.7582 | 30819221 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs | NA | 0.44 | 0.7582 | 22948659 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | Gemcitabine | FACs | NA | 0.44 | 0.7582 | 27349387 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs | NA | 0.44 | 0.7582 | 24231729 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs followed by Migration and Invasion assay | NA | 0.44 | 0.7582 | 27367674 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs followed by SFA | NA | 0.44 | 0.7582 | 27349387 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs followed by SP assay | NA | 0.44 | 0.7582 | 22963768 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs followed by Tumorigenicity assay | NA | 0.44 | 0.7582 | 22111082 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | Migration and Invasion assay followed by FACs | NA | 0.44 | 0.7582 | 22109279 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | Migration assay followed by FACs | NA | 0.44 | 0.7582 | 31856088 |
| ALDH1A1 | 402 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.4 | 0.684 | 34794402 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay and ALDEFLUOR assay followed by Western Blotting and SFA | NA | 0.4 | 0.684 | 32781084 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | ALDEFLUOR assay | NA | 0.4 | 0.684 | 30747824 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | Migration and Invasion assay followed by FACs | NA | 0.4 | 0.684 | 22109279 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | Western Blotting followed by FACs | NA | 0.4 | 0.456 | 28775772 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by Western Blotting and SFA | NA | 0.4 | 0.456 | 32781084 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | Gemcitabine | qRT-PCR | NA | 0.4 | 0.456 | 23026911 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs | NA | 0.4 | 0.456 | 22948659 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs followed by SP assay | NA | 0.4 | 0.456 | 22963768 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | Migration and Invasion assay followed by FACs | NA | 0.4 | 0.456 | 22109279 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | Migration assay followed by FACs | NA | 0.4 | 0.456 | 31856088 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by FACs | NA | 0.4 | 0.456 | 30819221 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | Western Blotting followed by FACs | NA | 0.4 | 0.211 | 28775772 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by Western Blotting and SFA | NA | 0.4 | 0.211 | 32781084 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | Gemcitabine | qRT-PCR | NA | 0.4 | 0.211 | 23026911 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by SFA and qRT-PCR | NA | 0.4 | 0.211 | 30466404 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs | NA | 0.4 | 0.211 | 22948659 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs followed by SP assay | NA | 0.4 | 0.211 | 22963768 |
| BMI1 | 1066 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | Western Blotting | NA | 0.28 | 0.1135 | 23437065 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by Western Blotting and SFA | NA | 0.28 | 1 | 32781084 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | Gemcitabine | qRT-PCR | NA | 0.28 | 1 | 23026911 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by SFA and qRT-PCR | NA | 0.28 | 1 | 30466404 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by SFA and qRT-PCR | NA | 0.28 | 1 | 30466404 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs | NA | 0.28 | 1 | 22948659 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs | NA | 0.28 | 1 | 24231729 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs followed by SFA | NA | 0.28 | 1 | 27349387 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs followed by SP assay | NA | 0.28 | 1 | 22963768 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs followed by Tumorigenicity assay | NA | 0.28 | 1 | 22111082 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | Migration and Invasion assay followed by FACs | NA | 0.28 | 1 | 22109279 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | Migration assay followed by FACs | NA | 0.28 | 1 | 31856088 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by FACs | NA | 0.28 | 1 | 30819221 |
| CTNNB1 | 2514 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by Western Blotting and SFA | NA | 0.28 | 0.0647 | 32781084 |
| PAF1 | 25459 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by Western Blotting and SFA | NA | 0.28 | 0.0032 | 32781084 |
| PHF5A | 18000 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by Western Blotting and SFA | NA | 0.28 | 0.0011 | 32781084 |
| ZG16B | 30456 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 29100320 |
| MIR100 | 31487 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 21785383 |
| B3GNT2 | 15629 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by PCR array assay and qRT-PCR | Up | 0.24 | 0.0011 | 30466404 |
| B3GNT3 | 13528 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by PCR array assay and qRT-PCR | Up | 0.24 | 0.0042 | 30466404 |
| GALNT12 | 19877 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by PCR array assay and qRT-PCR | Up | 0.24 | 0.0032 | 30466404 |
| GALNT16 | 23233 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by PCR array assay and qRT-PCR | Up | 0.24 | 0.0021 | 30466404 |
| GALNT3 | 4125 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by PCR array assay and qRT-PCR | Up | 0.24 | 0.0042 | 30466404 |
| MGAT4A | 7047 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by PCR array assay and qRT-PCR | Up | 0.24 | 0.0032 | 30466404 |
| MIR106A | 31494 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 21785383 |
| MIR125B1 | 31506 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0042 | 21785383 |
| MIR192 | 31562 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 21785383 |
| MIR429 | 13784 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 21785383 |
| MIR99A | 31650 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 21785383 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by qRT-PCR | NA | 0.2 | 0.1739 | 30819221 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by SFA and qRT-PCR | NA | 0.2 | 0.1739 | 30466404 |
| ACVR1 | 171 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by qRT-PCR | NA | 0.2 | 0.0011 | 30819221 |
| KRT19 | 6436 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by qRT-PCR | NA | 0.2 | 0.0074 | 30819221 |
| NES | 7756 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SP assay followed by qRT-PCR | NA | 0.2 | 0.0573 | 30819221 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | FACs followed by Tumorigenicity assay | NA | 0.12 | 0.456 | 22111082 |
| FLOT2 | 3758 | LTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | Migration assay followed by FACs | NA | 0.12 | 0.0032 | 31856088 |
| AGPAT4 | 20885 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34794402 |
| AKR1C3 | 386 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34794402 |
| CTSD | 2529 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34794402 |
| DYNC1I1 | 2963 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34794402 |
| FMNL2 | 18267 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34794402 |
| GAPDH | 4141 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34794402 |
| GLRX | 4330 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34794402 |
| HSP90AA1 | 5253 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0064 | 34794402 |
| HSP90AB1 | 5258 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0074 | 34794402 |
| HSP90B1 | 12028 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34794402 |
| HSPA5 | 5238 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0117 | 34794402 |
| HSPA5 | 5238 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0117 | 34794402 |
| HSPB1 | 5246 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34794402 |
| KRT1 | 6412 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34794402 |
| KRT9 | 6447 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34794402 |
| PIK3CA | 8975 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34794402 |
| TF | 11740 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34794402 |
| TIMP1 | 11821 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34794402 |
| TP11 | NA | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34794402 |
| TUBB3 | 20772 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34794402 |
| VIM | 12692 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Proteomics | Up | 0.08 | 0.017 | 34794402 |
| MIR142 | 31529 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 21785383 |
| MIR154 | 31541 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383 |
| MIR155 | 31542 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 21785383 |
| MIR15B | 31544 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0085 | 21785383 |
| MIR195 | 31566 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 21785383 |
| MIR19A | 31574 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 21785383 |
| MIR29A | 31616 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 21785383 |
| MIR29B1 | 31619 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 21785383 |
| MIR302d | 31765 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383 |
| MIR373 | 31787 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383 |
| MIR384 | 31878 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383 |
| MIR424 | 31881 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 21785383 |
| MIR448 | 26069 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383 |
| MIR485 | 32067 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383 |
| MIR489 | 32074 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383 |
| MIR497 | 32088 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 21785383 |
| MIR498 | 32092 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383 |
| MIR512-1 | 32090 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383 |
| MIR517B | 32115 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383 |
| MIR518e | 32119 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383 |
| MIR526B | 32100 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383 |
| MIR549A | 32803 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 21785383 |
| MIR551A | 32806 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383 |
| MIR559 | 32815 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383 |
| MIR575 | 32831 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383 |
| MIR599 | 32855 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383 |
| MIR625 | 32881 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383 |
| MIR630 | 32886 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383 |
| MIR641 | 32897 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383 |
| MIR645 | 32901 | HTM | Pancreatic Cancer | Adenocarcinoma | Capan-1 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383 |